Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

BMS 270394 is an agonist of retinoic acid receptor γ (RARγ; EC50 = 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 (Item No. 29380).1 It is selective for RARγ over RARβ (EC50 = 400 nM) and is inactive at RARα. BMS 270394 synergizes with paclitaxel (Item No. 10461) to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.2
WARNING This product is not for human or veterinary use.
1. Enantiomer discrimination illustrated by high-
2. Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Res. 61(24), 8703-8711 (2001).